Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02588651
Title A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Deepa Jagadeesh

mature T-cell and NK-cell lymphoma

adult T-cell leukemia/lymphoma


Brentuximab vedotin

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Michigan Withdrawn Ann Arbor Michigan 48109-5413 United States Details
Wayne State University, Karmanos Cancer Institute Recruiting Detroit Michigan 48201 United States Details
Hackensack University Medical Center Completed Hackensack New Jersey 07601 United States Details
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center Completed Cleveland Ohio 44106 United States Details
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center Recruiting Cleveland Ohio 44195 United States Details
*Shaded cells indicate that there was no data available from for the field